Yun Yao converts preferred into 41.99M Indaptus (INDP) shares
Rhea-AI Filing Summary
Indaptus Therapeutics, Inc. reported that investor Yun Yao is a more than 10% owner with 41,991,000 shares of common stock. These shares arose from a securities purchase agreement under which Yao acquired Series AA and Series AAA Convertible Non-Redeemable Preferred Stock and then converted all of it into common shares following the closing on March 23, 2026.
Positive
- None.
Negative
- None.
Insights
Yun Yao now holds 41,991,000 Indaptus common shares via preferred conversions.
The filing shows that Yun Yao acquired 196,800 shares of Series AA and 253,700 shares of Series AAA Convertible Non-Redeemable Preferred Stock under a securities purchase agreement dated March 19, 2026. These preferred shares were then fully converted to common stock after closing on March 23, 2026.
Each Series AA share converts into 20 common shares, and each Series AAA share converts into 150 common shares. The conversion produced 3,936,000 common shares from Series AA and 38,055,000 from Series AAA, totaling 41,991,000 common shares. This position is reported as held directly and makes Yao a more than 10% owner.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. On March 19, 2026, Yun Yao (the "Reporting Person"), the other purchasers and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired 196,800 shares of Series AA Convertible Non-Redeemable Preferred Stock and 253,700 shares of Series AAA Convertible Non-Redeemable Preferred Stock (together, the "Preferred Stock"). Each share of Series AA Preferred Stock is convertible into 20 shares of common stock, and each share of Series AAA Preferred Stock is convertible into 150 shares of common stock. Following the closing on March 23, 2026, the Reporting Person converted all Preferred Stock, resulting in the issuance of 41,991,000 shares of common stock (3,936,000 from Series AA and 38,055,000 from Series AAA).
Key Figures
Key Terms
Series AA Convertible Non-Redeemable Preferred Stock financial
Series AAA Convertible Non-Redeemable Preferred Stock financial
securities purchase agreement financial
convertible financial
Preferred Stock financial
FAQ
Who is the reporting person in Indaptus Therapeutics (INDP) latest Form 3?
What preferred stock did Yun Yao acquire in Indaptus Therapeutics (INDP)?
What are the conversion ratios for Indaptus (INDP) Series AA and Series AAA preferred stock?
Does the Form 3 for Indaptus (INDP) report any remaining preferred stock for Yun Yao?
AI-generated analysis. How Rhea-AI works. Not financial advice.